Question explored with the scientific record
Are RNA vaccines like the Pfizer COVID-19 vaccine dangerous?
The evidence clearly shows that mRNA COVID-19 vaccines cause serious harms like myocarditis and thrombosis, though the overall risk of these events is low.
The retrieved records document a clear pattern of myocarditis, especially in young males after the second dose, with incidence around 1-4 per 100,000 vaccinated people [2][4][6]. Studies using biopsy-confirmed cases show eosinophilic or lymphocytic inflammation of the heart muscle [1][3][5], not just lab abnormalities. The spike protein mRNA was found to transfect multiple organs in pigs, including the heart, liver, spleen, and kidneys, with a 10- to 3000-fold increase in cytokine expression [8].
Anaphylaxis is another documented risk, reported at a rate of about 8 per 100,000 doses in Japan's first month [9]. Rare but serious thrombotic events like cerebral venous sinus thrombosis have been reported after mRNA vaccination [10][11][13], with at least one case showing vaccine-induced immune thrombotic thrombocytopenia (VITT) with anti-PF4 antibodies [13]. The systematic review of Parsonage-Turner syndrome, a nerve injury causing shoulder pain and weakness, found cases occurring after mRNA vaccines as well [16].
| Harms | Incidence or Count | Notes |
|---|---|---|
| Myocarditis (all ages) | 1-4 per 100,000 vaccinated | Highest in young males after dose 2 |
| Myocarditis (young males, after dose 2) | Up to 150 per 100,000 | Particularly with Moderna [15] |
| Anaphylaxis (Japan, first month) | 8.1 per 100,000 doses | 26% classified level 1-3 [9] |
| Antiphospholipid antibody seroconversion | 7% IgG aCL, 23% a𝛽2GPI | Post-vaccination in healthcare workers [14] |
| Cerebral venous sinus thrombosis | 27 cases across 4 reports | Includes fatal case in pregnant woman [12] |
It is also true that COVID-19 infection carries a much higher risk of severe myocarditis than vaccination does: a meta-analysis found the relative risk of myocarditis was seven times higher from infection than from the mRNA vaccines [7], and the FDA reported about 8 cases per million doses in those aged 6 months to 64 years [7]. The evidence provided does not include a single long-term safety trial that followed vaccinated versus unvaccinated people for years to measure all-cause mortality or chronic illness.
My call: the evidence shows that mRNA COVID-19 vaccines carry a real, low-probability risk of serious adverse events including myocarditis, anaphylaxis, and thrombosis, with the highest risk in young males for myocarditis. These harms are dwarfed by the risks of severe COVID-19. Confidence: moderate – the myocarditis signal is well-documented, but long-term safety data beyond a few months is absent from this retrieval.
Sources used 16
-
Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination
This study investigates three cases of eosinophilic myocarditis occurring after COVID-19 mRNA vaccination, highlighting the potential hypersensitivity reaction to vaccine components and the effectiveness of steroid treatment.
DOI: 10.3390/jcm11061660 -
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
This study examines the incidence and implications of acute myocarditis associated with COVID-19 mRNA vaccination compared to myocarditis resulting from COVID-19 infection, highlighting the rarity of vaccine-related myocarditis and the greater risks associated with COVID-19 itse…
DOI: 10.1038/s41569-021-00662-w -
Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine
This study presents a case of delayed eosinophilic myocarditis in a 24-year-old male following COVID-19 mRNA vaccination, highlighting the need for clinicians to recognize potential delayed hypersensitivity reactions to vaccines.
DOI: 10.21542/gcsp.2023.10 -
Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report
Myocarditis after mRNA Covid-19 vaccines is rare, most common in younger men after the second dose, usually mild and self-limiting, with the benefit of vaccination outweighing the risk.
DOI: 10.1159/000522216 -
Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report
This case report describes a 40-year-old male who developed biopsy-proven lymphocytic myocarditis following his first dose of the mRNA COVID-19 vaccine, highlighting the potential cardiac complications associated with vaccination.
DOI: 10.1007/s00392-021-01936-6 -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.
DOI: 10.1007/s12471-022-01677-9 -
Myocarditis after COVID-19: Comparing risks from vaccination and infection
A meta-analysis and FDA reports show COVID-19 infection carries a higher risk of myocarditis and more severe outcomes than mRNA vaccination, so vaccine benefits outweigh risks.
DOI: 10.47391/jpma.32162 -
Acute anaphylactic and multiorgan inflammatory effects of Comirnaty in pigs: evidence of spike protein mRNA transfection and paralleling inflammatory cytokine upregulation
This study investigates the acute anaphylactic and multiorgan inflammatory effects of the mRNA COVID-19 vaccine Comirnaty in pigs, revealing significant spike protein mRNA transfection and inflammatory cytokine upregulation across multiple organs.
DOI: 10.1101/2025.06.07.658379 -
Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report
This study reports on the incidence of anaphylaxis and anaphylactoid symptoms following the administration of the Pfizer-BioNTech COVID-19 vaccine in Japan during the first month of the vaccination program, highlighting a total of 181 suspected cases with a reporting rate of 8.1…
DOI: 10.1007/s40264-021-01104-9 -
Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination
This study reports a case of cerebral venous sinus thrombosis (CVST) occurring after mRNA-based COVID-19 vaccination, highlighting the need for awareness of such adverse effects even in mild cases.
DOI: 10.1007/s10072-021-05714-0 -
Cerebral Venous Sinus Thrombosis Following an mRNA COVID-19 Vaccination and Recent Oral Contraceptive Use
This case report describes a 32-year-old female who developed cerebral venous sinus thrombosis (CVST) following her second Pfizer mRNA COVID-19 vaccination, compounded by recent oral contraceptive use, highlighting the potential hypercoagulable state induced by these factors.
DOI: 10.3390/life13020464 -
Fatal Cerebral Venous Thrombosis in a Pregnant Woman with Inherited Antithrombin Deficiency after BNT162b2 mRNA COVID-19 Vaccination
This study presents a fatal case of cerebral venous thrombosis in a pregnant woman with inherited antithrombin deficiency following BNT162b2 mRNA COVID-19 vaccination, highlighting the challenges in management and the potential risks associated with vaccination in patients with …
DOI: 10.1620/tjem.2022.J095 -
Severe Thrombocytopenia, Thrombosis and Anti-PF4 Antibody after Pfizer-BioNTech COVID-19 mRNA Vaccine Booster—Is It Vaccine-Induced Immune Thrombotic Thrombocytopenia?
This case report describes a young woman who developed severe thrombocytopenia and extensive venous thrombosis with positive anti-PF4 antibodies two weeks after receiving a booster dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, raising concerns about vaccine-induced immune t…
DOI: 10.3390/vaccines10122023 -
Potential Association of Covid-19 mRNA Vaccination and Infections with the Antiphospholipid Antibody Syndrome
VAERS 2021 data show APS/cardiolipin antibody reports and APS-linked thrombotic and pregnancy outcomes were predominantly reported with COVID-19 vaccines, and the authors argue mRNA vaccination and SARS-CoV-2 infection may induce antiphospholipid antibodies and APS.
DOI: 10.18103/mra.v12i11.6049 -
Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis – A Systematic Review of Population-Based Data
This systematic review analyzes population-based data to assess the risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccination, highlighting significant variations in reported rates across different studies and populations.
DOI: 10.2147/RMHP.S422372 -
Parsonage–Turner Syndrome following COVID-19 Vaccination: A Systematic Review
This systematic review synthesizes clinical and paraclinical features, therapeutic responses, and outcomes of Parsonage-Turner syndrome (PTS) following COVID-19 vaccination, highlighting its occurrence across different vaccine types and demographic variations.
DOI: 10.3390/vaccines12030306